Published in Medical Letter on the CDC and FDA, February 6th, 2005
According to recent research published in the Journal of Allergy and Clinical Immunology, "The Aerocrine exhaled nitric oxide (NO) monitoring system NIOX was cleared by the U.S. Food and Drug Administration for clinical application in patients with asthma in May 2003. The fractional concentration of exhaled NO has been extensively researched as a marker of airway inflammation in asthma and other diseases and is now poised to enter clinical application. The American Thoracic and European Respiratory Societies'...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.